Loading chat...
NY A02202
Bill
Status
1/15/2025
Primary Sponsor
Amy Paulin
Click for details
AI Summary
-
Expands the scope of diagnostic pharmaceuticals optometrists can use from only "surface of the eye" applications to include the eye "and adnexa" (surrounding structures like eyelids and tear ducts)
-
Removes the specific enumerated lists of permitted drug categories (such as mydriatics, cycloplegics, antibiotics, beta blockers, etc.) for diagnostic, therapeutic, and glaucoma treatment purposes
-
Broadens optometrists' prescribing authority to include any FDA-approved, commercially available topical pharmaceutical agents rather than limiting them to previously specified drug classes
-
Updates terminology in certification requirements, replacing outdated "phase one" and "phase two drugs" language with current descriptive terms for therapeutic pharmaceutical agent categories
-
Applies the same expanded scope (eye and adnexa) to topical therapeutic agents and glaucoma/ocular hypertension treatments
Legislative Description
Amends the definitions of diagnostic pharmaceuticals, topical therapeutic pharmaceutical agents, and therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension as they relate to the certification to use therapeutic drugs in the practice of optometry.
Last Action
referred to higher education
1/7/2026